Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

SciClone Collaborates with Soligenix on Oral Mucositis Treatment

publication date: Jul 8, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
SciClone Pharma has formed a collaboration with Soligenix, a New Jersey clinical-stage biopharma, to develop a personal medicine treatment for oral mucositis. SciClone will grant Soligenix access to its own oral mucositis clinical and regulatory data in return for China rights to SGX942, Soligenix’ novel treatment for the disorder. SciClone is a US company that distributes western drugs in China. Financial details of the pact were not disclosed. More details....

Stock Symbols: (NSDQ: SCLN) (OTCQB: SNGX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors